Dr. William W. King, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of North Carolina at Chapel Hill School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 750
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: University of North Carolina at Chapel Hill School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NC license 9300188
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Novant Health New Hanover Regional Medical Center Wilmington, NC
- Novant Health Brunswick Medical Center Supply, NC
- Columbus Regional Healthcare System Whiteville, NC
Medical groups
- Wilmington Gastroenterology Associates, PA (21 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 750
- Services billed
- 18,998
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 254 | 254 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 131 | 130 |
| Biopsy of large bowel using a flexible endoscope | 131 | 131 |
| Infusion, normal saline solution, 250 cc | 122 | 16 |
| Administration of chemotherapy into vein, 1 hour or less | 118 | 16 |
| Established patient office or other outpatient visit, 30-39 minutes | 95 | 88 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 80 | 80 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 73 | 71 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 39 | 39 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 36 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Wilmington, NC | 118 |
| Omeprazole Other prescribers in Wilmington, NC | 78 |
| Dicyclomine Hcl Other prescribers in Wilmington, NC | 26 |
| Balsalazide Disodium | 23 |
| Prednisone Other prescribers in Wilmington, NC | 15 |
| Stelara (ustekinumab) | 13 |
| Creon (lipase/protease/amylase) Other prescribers in Wilmington, NC | 12 |
| Ursodiol Other prescribers in Wilmington, NC | 12 |
| Linzess (linaclotide) Other prescribers in Wilmington, NC | 11 |
| Furosemide Other prescribers in Wilmington, NC | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 32 payments worth $698 in total to this clinician.
| AbbVie Inc. | $400 |
|---|---|
| Madrigal Pharmaceuticals | $144 |
| Pfizer Inc. | $47.74 |
| Aimmune Therapeutics, Inc. | $39.80 |
| Ardelyx, Inc. | $29.99 |
| Cook Medical LLC | $29.93 |
| Phathom Pharmaceuticals, Inc. | $6.17 |
| Food and Beverage | $698 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $269,519 in research payments for these studies, mostly to the institutions running them.
- A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
Boehringer Ingelheim International GmbH - A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD)
AbbVie Inc. - A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. · Completed · NCT01848561
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.